维普期刊资源整合服务平台（V6.5）

33篇 您的检索式：作者名="Bredel M"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	RTOG 0211:a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients显示文摘PURPOSE: To determine the safety and efficacy of gefitinib,an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,in combination with radiation for newly diagnosed glioblastoma(GBM) patients.METHODS AND MATERIALS: Between March 21,2002,and May 3,2004,Radiation Therapy Oncology Group(RTOG) 0211 enrolled 31 and 147GBM patients in the phase 1 and 2 arms,respectively.Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy(RT) and continued post RT for 18 months or until progression.Tissue microarrays from 68 cases were analyzed for EGFR expression.RESULTS: The maximum tolerated dose(MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs(non-EIAEDs).All patients in the phase 2 component were treated at a gefitinib dose of 500 mg;patients receiving EIADSs could be escalated to 750 mg.The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal.Median survival was 11.5 months for patients treated per protocol.There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone,matched by RTOG recursive partitioning analysis(RPA) class distribution.Younger age was significantly associated with better outcome.Per protocol stratification,EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients.CONCLUSIONS: The addition of gefitinib to RT is well tolerated.Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone.	Chakravarti A Wang M Robins HI Lautenschlaeger T Curran WJ Brachman DG Schultz CJ Choucair A Dolled-Filhart M Christiansen J Gustavson M Molinaro A Mischel P Dicker AP Bredel M Mehta M	2013	中国神经肿瘤杂志2013，11，1：	8
2	DNA topoisomerase Ⅱ alpha predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas 显示文摘	Bredel M Pollack IF Hamilton RL	2002	Int J Cancer2002，99，6：	1
3	NFKBIA deletion in glio- blastomas显示文摘	Bredel M Scholtens DM Yadav AK	2011	N Engl J Med2011，364，7：	1
4	High expression of DNA topoisomerase II alpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patients 显示文摘	Bredel M Piribauer M Marosi C	2002	Eur J Cancer2002，38，10：	1
5	Splintless orthognathic surgery: a novel technique using patient-specific implants (PSI) 显示文摘	Gander T Bredell M Eliades T	2015	J Craniomaxillofac Surg2015，43，3：	1
6	Tumor necrosis factoralpha induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human gliobastomas 显示文摘	Bredel M Bredel C Juric D	2006	J Clin Oncol2006，24，2：	1
7	The p21-ras signal transduction pathway and growth regulation in human high-grade gliomas显示文摘	BREDEL M POLLACK L F	1999	Brain Research Reviews1999，，23：	1
8	Tumor necrosis factor-alpha- induced protein 3 as a putative regulator of nuclear factor-kappaB- mediated resistance to O6-alkylating agents in human glioblastomas显示文摘	Bredel M Bredel C Juric D	2006	J Clin Oncol2006，24，：	1
9	NFKBIA deletion in glioblastomas显示文摘	BREDEL M SCHOLTENS D M YADAV AK	2011	N Engl J Med2011，364，7：	1
10	A network model of a cooperative genetic landscape in brain tumors显示文摘	BREDEL M SCHOLTENS DM HARSH GR	2009	JA- MA2009，302，3：	1
11	Expression of DNA topoisomerase IIalpha inoligodendroglioma显示文摘	Gatterbauer B Birner P	2002	Anticancer Res2002，22，2：	1
12	The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas显示文摘	Bredel M Pollak IF	1999	Brain Research Reviews1999，29，：	1
13	DNA topoisomerase IIalpha expression in optic pathwaygliomas of childhood显示文摘	Slavc I Birner P	2002	Eur J Cancer2002，38，3：	1
14	DNA topoisomerase IIalpha expression in optic pathway gliomas of childhood显示文摘	Bredel M Slavc I Birner P	2002	Eur J Cancer2002，38，3：	1
15	A network model of a cooperative genetic landscape in brain tumors显示文摘	Bredel M Schohens D M Harsh G R Bredel C Chandler J P Renfrow J J	2009	JAMA2009，302，：	1
16	DNA topoisomerase Ⅱαpredicts progression-free and overall survival in pediatric malignant non-brainstem gliomas显示文摘	Bredel M Pollack IF Hamilton RL	2002	Int J Cancer2002，99，6：	1
17	Chemogenomics:an emerging strategy for rapid target and drug discovery显示文摘	Bredel M Jacoby E	2004	Nat Rev Genet2004，5，4：	1
18	Brain-tumour drug resistance: the bare essentials显示文摘	Bredel M Zentner J	2002	Lancet Oncol2002，3，7：	1
19	Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas显示文摘	BREDEL M BREDEL C JURIC D	2005	Cancer Res2005，65，19：	1
20	A network model of a cooperative genetic landscape in brain tumors显示文摘	Bredel M Scholtens DM Harsh GR	2009	JAMA2009，302，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示